scholarly journals Metabolic syndrome and diabetes for the urologist

2014 ◽  
Vol 8 (7-8) ◽  
pp. 159 ◽  
Author(s):  
Neil E. Fleshner ◽  
Bimal Bhindi
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Benign Prostatic Hyperplasia ◽  
Clinical Data ◽  
Prostatic Hyperplasia ◽  
Prostatic Diseases ◽  
Viable Treatment

Type 2 diabetes has a number of know urological consequences. Epidemiologic and clinical data suggest a link between metabolic syndrome and prostatic diseases such as benign prostatic hyperplasia (BPH) and prostate cancer. Recent studies have identified metformin as a viable treatment for patients with type 2 diabetes and prostate cancer.

scholarly journals The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective

Medicines ◽  
2021 ◽  
Vol 8 (6) ◽  
pp. 30
Author(s):  
Teow J. Phua
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cell Biology ◽  
Cancer Biology ◽  
Cost Savings ◽  
Prostatic Hyperplasia ◽  
Biological Processes ◽  
New Perspective ◽  
Prostatic Diseases

Background: The etiology of benign prostatic hyperplasia and prostate cancer are unknown, with ageing being the greatness risk factor. Methods: This new perspective evaluates the available interdisciplinary evidence regarding prostate ageing in terms of the cell biology of regulation and homeostasis, which could explain the timeline of evolutionary cancer biology as degenerative, inflammatory and neoplasm progressions in these multifactorial and heterogeneous prostatic diseases. Results: This prostate ageing degeneration hypothesis encompasses the testosterone-vascular-inflamm-ageing triad, along with the cell biology regulation of amyloidosis and autophagy within an evolutionary tumorigenesis microenvironment. Conclusions: An understanding of these biological processes of prostate ageing can provide potential strategies for early prevention and could contribute to maintaining quality of life for the ageing individual along with substantial medical cost savings.

scholarly journals A Review on Serenoa serrulata: A Potential Medicinal Plant for Prostatic Diseases

2021 ◽  
Vol 3 (1) ◽  
pp. 19-33
Author(s):  
Jacqueline Aber ◽  
Bruhan Kaggwa ◽  
Hedmon Okella ◽  
Clement Olusoji Ajayi ◽  
Patrick Engeu Ogwang
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Adverse Effects ◽  
Medicinal Plant ◽  
Cucurbita Pepo ◽  
Prostatic Hyperplasia ◽  
Research Articles ◽  
Echinacea Angustifolia ◽  
Saw Palmetto ◽  
Prostatic Diseases

Background: Prostatic diseases which include prostatitis, benign prostatic hyperplasia (BPH) and prostate cancer are the benign or malignant disorders that affect the prostate. Phytotherapies have been adopted as the alternative treatment/ management option especially for BPH since the current modern methods of treatment presents a lot of adverse effects. Methodology: The literature was searched using different databases including Medline/PubMed, Cochrane library, Scopus, Proquest library, Embase, EBooks and Google Scholar for relevant records for a period from 1988 to 2018 to identify all the published articles of S. serrulata regarding treatment of prostatic diseases. The key search terms were Serenoa serrulata, S. repens, Saw palmetto, Prostate cancer treatment with Serenoa serrulata, treatment of Benign Prostatic Hyperplasia with Serenoa serrulata,  phytochemicals of Serenoa serrulata, ethnobotanical uses of Serenoa serrulata, toxicity of Serenoa serrulata, pharmacological activities of Serenoa serrulata and also traditional management and treatment of prostatic diseases  using Serenoa serrulata and also clinical trials on treatment of prostatic diseases  with Serenoa serrulata. The retrieved articles were reviewed, synthesized and analyzed qualitatively. The reference list of the retrieved articles was also reviewed and synthesized. The original research articles which reported an investigation of S. serrulata of any study design, original published research articles, any time of publication and grey literature (conference papers, reported articles, academic thesis) were included. The articles whose full texts were not freely available by the time of search and those without clear information about methodology and study design were excluded. Results: This review reported that Serenoa serrulata belonging to the Arecaceae family commonly known as saw palmetto is used traditionally for treating prostatic disease conditions and other infertility conditions in both men and women. Phytochemical screening of hexanic and ethanolic extracts of S. serrulata comprised of free fatty acids and phytosterols which together contribute to their antiprostatic activities. These extracts of S. serrulata exhibited antiandrogenic, anti-inflammatory and anti-proliferative activities through inhibition of both isoenzymes 5α- reductase and inhibition of binding of dihydrotestosterone (DHT) to the cytosolic androgen receptors. This is a similar mechanism exhibited by finasteride and Tamsulosin both antiprostatic conventional drugs though the plant phytochemicals do not interfere with PSA secretion. S. serrulata has also been reported to be non-toxic in both non clinical and clinical trial studies. The medicinal plants reported by this review to be used in combination include; stinging nettle (Urtica dioca), Zingiber officinalis, Echinacea angustifolia and pumpkin (Cucurbita pepo). The antiprostatic conventional drugs reported include finasteride and Tamsulosin. Conclusion and Recommendation: The results showed that S. serrulata is effective in treating prostatic diseases. The potency and safety is improved when used in combination with Urtica dioca, Cucurbita pepo, Zingiber officinalis and Echinacea angustifolia as compared with anti-prostatic conventional drugs Finasteride and Tamsulosin alone. The plant combination has also been shown to have improvement in the quality of life and as well enhancing the synergy of Finasteride and Tamsulon and their adverse effects. Effective medicinal plant combinations should be formulated into products and integrated into the usual treatment for prostatic diseases.

scholarly journals Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia

Diabetologia ◽  
2005 ◽  
Vol 48 (4) ◽  
pp. 784-789 ◽  
Author(s):  
A. P. Berger ◽  
M. Deibl ◽  
E. J. Halpern ◽  
M. Lechleitner ◽  
J. Bektic ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Risk Factor ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Vascular Damage

Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases

Urology ◽  
2004 ◽  
Vol 64 (4) ◽  
pp. 707-711 ◽  
Author(s):  
Clemens BrÖssner ◽  
Karin Petritsch ◽  
Klaus Fink ◽  
Marco Auprich ◽  
Stephan Madersbacher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Tissue Levels ◽  
Prostatic Diseases

69 Phyto-oestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association to prostatic diseases

2004 ◽  
Vol 3 (2) ◽  
pp. 20
Author(s):  
C. Brössner ◽  
K. Petritsch ◽  
K. Fink ◽  
M. Auprich ◽  
S. Madersbacher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Tissue Levels ◽  
Prostatic Diseases

468: Polymorphic CA Repeats in IGF-I Gene is a Common Genetic Modifier in the Etiology of Prostate Cancer and Benign Prostatic Hyperplasia

2004 ◽  
Vol 171 (4S) ◽  
pp. 125-125
Author(s):  
Lizhong Wang ◽  
Kazunari Sato ◽  
Norihiko Tsuchiya ◽  
Chikara Ohyama ◽  
Shigeru Satoh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Genetic Modifier ◽  
Prostatic Hyperplasia ◽  
Igf I ◽  
I Gene

453-P: Metabolic Syndrome Severity Score, All-Cause Mortality, and Incident Vascular Events in Type 2 Diabetes: A 13-Year, Single-Centre, Follow-Up Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 453-P
Author(s):  
MONIA GAROFOLO ◽  
ELISA GUALDANI ◽  
DANIELA LUCCHESI ◽  
LAURA GIUSTI ◽  
VERONICA SANCHO-BORNEZ ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Severity Score ◽  
Single Centre ◽  
Vascular Events ◽  
Follow Up Study ◽  
All Cause Mortality
Sign in / Sign up

Export Citation Format

Share Document